Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sing-Huang Tan

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Therapeutic Advances in Medical Oncology|December 26, 2022
Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in AsiaJia Li Low, Elaine Lim, Lavina Bharwani, et al.
Scientific Reports|June 15, 2016
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursRoss Andrew Soo, Nicholas Syn, Soo-Chin Lee, et al.
BMC Cancer|November 18, 2020
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursYvonne L E Ang, Gwo Fuang Ho, Ross A Soo, et al.
Breast Cancer Research and Treatment|December 20, 2021
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancerKritika Yadav, Joline Lim, Joan Choo, et al.
Oncotarget|September 1, 2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerAndrea L A Wong, Raghav Sundar, Ting-Ting Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Therapeutic Advances in Medical Oncology|December 26, 2022
Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in AsiaJia Li Low, Elaine Lim, Lavina Bharwani, et al.
Scientific Reports|June 15, 2016
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursRoss Andrew Soo, Nicholas Syn, Soo-Chin Lee, et al.
BMC Cancer|November 18, 2020
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursYvonne L E Ang, Gwo Fuang Ho, Ross A Soo, et al.
Breast Cancer Research and Treatment|December 20, 2021
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancerKritika Yadav, Joline Lim, Joan Choo, et al.
Oncotarget|September 1, 2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerAndrea L A Wong, Raghav Sundar, Ting-Ting Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Pageof 3